Cargando…
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study
BACKGROUND: Estimating quality of life (QoL) in patients with breast cancer is of importance in assessing treatment outcomes. Adjuvant endocrine therapy is widely used for hormone receptor-positive (HR+) early-stage breast cancer (EBC), and evidence suggests that aromatase inhibitors (AIs) may impro...
Autores principales: | Cao, Ayong, Zhang, Jin, Liu, Xiaoan, Wu, Weizhu, Liu, Yinhua, Fan, Zhimin, Zhang, Anqin, Zhou, Tianning, Fu, Peifen, Wang, Shu, Ouyang, Quchang, Tang, Jinhai, Jiang, Hongchuan, Zhang, Xiaohua, Pang, Da, He, Jianjun, Shi, Linxiang, Wang, Xianming, Sheng, Yuan, Mao, Dahua, Shao, Zhimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806477/ https://www.ncbi.nlm.nih.gov/pubmed/27009092 http://dx.doi.org/10.1186/s12955-016-0446-2 |
Ejemplares similares
-
Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006) -
Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013) -
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020) -
Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005) -
Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)